Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Since its first report in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a grave threat to public health. Virus-specific countermeasures, such as vaccines and therapeutics, have been developed and have contributed to the control of the viral pandemic, which has become endemic. Nonetheless, new variants continue to emerge and could cause a new pandemic. Consequently, it is important to comprehensively understand viral evolution and the roles of mutations in viral infectivity and transmission. SARS-CoV-2 beta variant encode mutations (D614G, N501Y, E484K, and K417N) in the spike which are frequently found in other variants as well. While their individual role in viral infectivity has been elucidated against various therapeutic antibodies, it still remains unclear whether those mutations may act additively or synergistically when combined. Here, we report that N501Y mutation shows differential effect on two therapeutic antibodies tested. Interestingly, the relative importance of E484K and K417N mutations in antibody evasion varies depending on the antibody type. Collectively, these findings suggest that continuous efforts to develop effective antibody therapeutics and combinatorial treatment with multiple antibodies are more rational and effective forms of treatment.
Abstract
Since its first report in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a grave threat to public health. Virus-specific countermeasures, such as vaccines and therapeutics, have been developed and have contributed to the control of the viral pandemic, which has become endemic. Nonetheless, new variants continue to emerge and could cause a new pandemic. Consequently, it is important to comprehensively understand viral evolution and the roles of mutations in viral infectivity and transmission. SARS-CoV-2 beta variant encode mutations (D614G, N501Y, E484K, and K417N) in the spike which are frequently found in other variants as well. While their individual role in viral infectivity has been elucidated against various therapeutic antibodies, it still remains unclear whether those mutations may act additively or synergistically when combined. Here, we report that N501Y mutation shows differential effect on two therapeutic antibodies tested. Interestingly, the relative importance of E484K and K417N mutations in antibody evasion varies depending on the antibody type. Collectively, these findings suggest that continuous efforts to develop effective antibody therapeutics and combinatorial treatment with multiple antibodies are more rational and effective forms of treatment.
참고문헌 (43)
- Tegally H, "Detection of a SARS-CoV-2 variant of concern in South Africa", Nature, 592, pp.438~443 (2021)
- Kim Eun-Ha, "Antiviral effects of human placenta hydrolysate (Laennec®) against SARS-CoV-2 in vitro and in the ferret model", The Journal of Microbiology, 59(11), pp.1056~1062 (2021), 한국미생물학회[DOI]
- Kim Chulwoo, "Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2", The Journal of Microbiology, 60(3), pp.335~346 (2022), 한국미생물학회[DOI]
- Kim Young-Il, "Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models", The Journal of Microbiology, 60(3), pp.255~267 (2022), 한국미생물학회[DOI]
- Lee Mi-Hyun, "COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity", The Journal of Microbiology, 60(3), pp.321~334 (2022), 한국미생물학회[DOI]
- Mattoo Sameer-ul-Salam, "T cell responses to SARS-CoV-2 in humans and animals", The Journal of Microbiology, 60(3), pp.276~289 (2022), 한국미생물학회[DOI]
- Myoung J, "Two years of COVID-19 pandemic: where are we now?", J. Microbiol, 60, pp.235~237 (2022)
- 박운이, "Protective and pathogenic role of humoral responses in COVID-19", The Journal of Microbiology, 60(3), pp.268~275 (2022), 한국미생물학회[DOI]
- Lee Hee-Jung, "Antiviral Activity Against SARS-CoV-2 Variants Using in Silico and in Vitro Approaches", The Journal of Microbiology, 61(7), pp.703~711 (2023), 한국미생물학회[DOI]
- 구근본, "Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2", Journal of Microbiology and Biotechnology, 30(12), pp.1843~1853 (2020), 한국미생물·생명공학회[DOI]
- Mattoo Sameer-ul-Salam, "A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization", Journal of Microbiology and Biotechnology, 31(12), pp.1601~1614 (2021), 한국미생물·생명공학회[DOI]
- Zhou Yong-Fei, "Expression and Immunogenicity of SARSCoV- 2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein", Journal of Microbiology and Biotechnology, 32(10), pp.1335~1343 (2022), 한국미생물·생명공학회[DOI]
- Minskaia E, "Discovery of an RNA virus 3?→5? exoribonuclease that is critically involved in coronavirus RNA synthesis", Proc. Natl. Acad. Sci. USA, 103, pp.5108~5113 (2006)
- Eckerle LD, "Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing", PLoS Pathog, 6, pp.e1000896~ (2010)
- Tao K, "The biological and clinical significance of emerging SARS-CoV-2 variants", Nature Rev. Genet, 22, pp.757~773 (2021)
- Jeong Hye Won, "Differences in seroprevalence between epicenter and non-epicenter areas of the COVID-19 outbreak in South Korea", The Journal of Microbiology, 59(5), pp.530~533 (2021), 한국미생물학회[DOI]
- 나운성, "A comprehensive review of SARS-CoV-2 genetic mutations and lessons from animal coronavirus recombination in one health perspective", The Journal of Microbiology, 59(3), pp.332~340 (2021), 한국미생물학회[DOI]
- Soh Sandrine M., "The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance", The Journal of Microbiology, 59(9), pp.807~818 (2021), 한국미생물학회[DOI]
- Chemaitelly H, "Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant", New Engl. J. Med, 385, pp.2585~2586 (2021)
- Riou C, "Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity", Sci. Transl. Med, 14, pp.eabj6824~ (2022)
- Zhang J, "Structural impact on SARS-CoV-2 spike protein by D614G substitution", Science, 372, pp.525~530 (2021)
- Li Q, "The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity", Cell, 182, pp.1284~1294 e1289 (2020)
- Motozono C, "SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity", Cell Host Microbe, 29, pp.1124~1136 e1111 (2021)
- Khan A, "Higher infectivity of the SARS-CoV-2 new variants is associated with K417N", T, E484K, and N501Y mutants: An insight from structural data, 2021, pp.236, 7045~7057
- Jeong JY, "One-step sequence- and ligation-independent cloning as a rapid and versatile cloning method for functional genomics studies", Appl. Environ. Microbiol, 78, pp.5440~5443 (2012)
- Islam MN, "Optimizing T4 DNA polymerase conditions enhances the efficiency of one-step sequence- and ligation-independent cloning", Biotechniques, 63, pp.125~130 (2017)
- 배소정, "Chikungunya Virus nsP2 Impairs MDA5", RIG-I-Mediated Induction of NF-κB Promoter Activation: A Potential Target for Virus-Specific Therapeutics, 2020, pp.30(12), 1801~1809[DOI]
- 이정윤, "Zika Virus-Encoded NS2A and NS4A Strongly Downregulate NF-κB Promoter Activity", Journal of Microbiology and Biotechnology, 30(11), pp.1651~1658 (2020), 한국미생물·생명공학회[DOI]
- 이희정, "Pine Needle Extract Applicable to Topical Treatment for the Prevention of Human Papillomavirus Infection", Journal of Microbiology and Biotechnology, 31(1), pp.137~143 (2021), 한국미생물·생명공학회[DOI]
- 김승택, "COVID-19 Drug Development", Journal of Microbiology and Biotechnology, 32(1), pp.1~5 (2022), 한국미생물·생명공학회[DOI]
- Lee Su Jin, "Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2", Journal of Microbiology and Biotechnology, 32(9), pp.1073~1085 (2022), 한국미생물·생명공학회[DOI]
- Walls AC, "Structure, dunction, and antigenicity of the SARS-CoV-2spike glycoprotein", Cell, 183, pp.1735~ (2020)
- Letko M, "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses", Nat. Microbiol, 5, pp.562~569 (2020)
- Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 e278 (2020)
- Wrobel AG, "Evolution of the SARS-CoV-2 spike protein in the human host", Nat. Commun, 13, pp.1178~ (2022)
- Weissman D, "D614G Spike mutation increases SARS CoV-2susceptibility to neutralization", Cell Host Microbe, 29, pp.23~31 e24 (2021)
- Kim YJ, "The impact on infectivity and neutralization efficiency of SARS-CoV-2 lineage B.1.351 pseudovirus", Viruses, 13, pp.633~ (2021)
- Cele S, "Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma", Nature, 593, pp.142~146 (2021)
- Salleh MZ, "Structural evaluation of the spike glycoprotein variants on SARS-CoV-2 transmission and immune evasion", Int. J. Mol. Sci, 22, pp.7425~ (2021)
- Tao K, "The biological and clinical significance of emerging SARS-CoV-2 variants", Nat. Rev. Genet, 22, pp.757~773 (2021)
- Baum A, "SARS-CoV-2 spike therapeutic antibodies in the age of variants", J. Exp. Med, 218, pp.e20210198~ (2021)
- Starr TN, "Deep mutational scanning of SARS-CoV-2receptor binding domain reveals constraints on folding and ACE2 binding", Cell, 182, pp.1295~1310 e1220 (2020)
- Volz E, "Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England", Nature, 593, pp.266~269 (2021)